Keytruda (Pembrolizumab) is one of the most advanced and widely recognized cancer treatments available today. As part of the new generation of immunotherapy drugs, Keytruda has transformed oncology care worldwide and given hope to thousands of patients, including many in Egypt and the MENA region.
What is Keytruda?
Keytruda is an immune checkpoint inhibitor that belongs to the class of PD-1 inhibitors. The drug works by blocking the PD-1 protein on immune cells, which cancer cells normally use to escape detection. By stopping this “immune evasion,” Keytruda activates the body’s immune system to identify and destroy cancer cells.
This innovative approach has made Keytruda a cornerstone in the treatment of multiple advanced cancers.
Uses of Keytruda (Indications)
Keytruda is approved and widely used in the treatment of:
-
Non-small cell lung cancer (NSCLC)
-
Advanced melanoma (skin cancer)
-
Head and neck cancers
-
Kidney cancer
-
Bladder cancer
-
Colorectal cancer (with specific biomarkers)
-
Certain types of lymphoma
Eligibility for Keytruda treatment is often determined by tests such as PD-L1 expression or other genetic markers, ensuring that the right patients benefit most.
How is Keytruda Given?
-
Keytruda is administered as an intravenous (IV) infusion in a hospital or cancer center.
-
The infusion typically takes around 30 minutes.
-
Depending on the treatment plan, patients usually receive a dose every 3 or 6 weeks.
Possible Side Effects of Keytruda
Because Keytruda stimulates the immune system, it may cause immune-related side effects, such as:
-
Fatigue and weakness
-
Loss of appetite
-
Rash or itching
-
Cough or shortness of breath
-
Thyroid or liver function changes
-
Diarrhea or colitis
Close monitoring by an oncologist is essential during Keytruda treatment to manage side effects effectively.
Contraindications
Keytruda may not be suitable for:
-
Patients with severe allergies to its components
-
Patients who have undergone organ transplantation
-
Those on strong immunosuppressive therapy
Manufacturer of Keytruda
Keytruda is manufactured by Merck & Co., a leading global pharmaceutical company known for its innovation and reliability in oncology care.
Keytruda in Egypt with Macrocare
In Egypt, Keytruda is available through specialized oncology centers. However, due to its high cost and the complexity of cancer care, patients often need professional coordination and guidance.
At Macrocare, we support patients by:
-
Connecting you with top oncologists in Egypt and abroad
-
Organizing treatment plans that include Keytruda
-
Providing end-to-end medical tourism services: travel, hospital admission, and aftercare
-
Ensuring patients and families have full support throughout their cancer journey
Conclusion
Keytruda (Pembrolizumab) is more than just a drug – it represents a breakthrough in how we fight cancer. While its price remains high, the effectiveness of Keytruda in improving survival and treatment outcomes has made it one of the most in-demand therapies worldwide.
With Macrocare, patients in Egypt and beyond can access world-class oncology care, including Keytruda treatment, supported by a team dedicated to guiding them every step of the way.
Contact Macrocare today to learn more about how Keytruda could be part of your personalized cancer treatment plan.
